Abstract
e16546Background: Nivolumab is a human IgG4 programmed death-1 immune checkpoint inhibitor antibody approved for use in multiple cancers. Nivolumab is approved for use as second line therapy in Ren...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
